Google
STOK — STOKE THERAPEUTICS INC (Healthcare >> Biotechnology)
STOK FAQ
What is STOK's ROE?
STOKE THERAPEUTICS INC reports a Return on Equity (ROE) of -42.99%.
What is STOK's dividend yield?
STOKE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is STOK's Deepscope Quality Score?
Deepscope rates STOK's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy STOK?
Deepscope's AI Timing Score for STOK is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does STOK belong to?
STOKE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 29.82
Price
0.46
(1.57%)
Day Change
|
|
|---|
STOK, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 29.82 |
| PBV / Sector |
4.63 / 4.91
|
| Earning Per Share | -2.77 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
14.73 M
GREAT
|
| Average 1W Daily Value |
12.83 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:46 |
| Symbol | STOK |
| Name | STOKE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 62.28 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,828.59 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730
Phone: 781 430 8200
Website: https://www.stoketherapeutics.com
Employees: 170
Sector: Healthcare >> Biotechnology
Description: Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
